News
Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
Title: OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent …
2024-04-11
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform.
Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 …
2024-03-18
OBI Pharma to present the Study Results of OBI-992 at the 14th World ADC London
OBI Pharma is excited to announce that Dr. Ming-Tain Lai, …
2024-03-12
OBI announces the termination of OBI-3424 Phase II trial
Following a strategic portfolio review, the Board of Directors of …
2024-03-11
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
First clinical trial to evaluate the safety and efficacy of …
2024-01-03
Kung-Yee Liang, PH.D. was elected as the chairman of OBI Pharma, Inc.
OBI Pharma, Inc. (4174.TWO) held a board meeting today (29th) …
2023-12-29
OBI Pharma proprietary ADC technology platform “plug and play”
site-specific conjugation, scalable manufacturing process, and suitability for various antibodies, …
2023-12-06
OBI Achieves ISO/IEC 27001 International Information Security Certification
After two years of continuous effort, OBI has successfully established …
2023-11-23
OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. appointed as Chief Executive Officer
Dr. Wang appointed by the OBI Pharma Board of Directors …
2023-06-02